Targeting HDACs: A Promising Therapy for Alzheimer's Disease

被引:147
|
作者
Xu, Ke [2 ]
Dai, Xue-Ling [1 ,3 ]
Huang, Han-Chang [1 ]
Jiang, Zhao-Feng [1 ,4 ]
机构
[1] Beijing Union Univ, Coll Arts & Sci, Beijing 100191, Peoples R China
[2] Capital Normal Univ, Coll Life Sci, Beijing 100048, Peoples R China
[3] Peking Univ, Dept Physiol & Pathophysiol, Sch Basic Med Sci, Beijing 100191, Peoples R China
[4] Beijing Union Univ, Beijing Key Lab Bioact Subst & Funct Foods, Beijing 100191, Peoples R China
基金
中国国家自然科学基金;
关键词
HISTONE DEACETYLASE INHIBITORS; MOUSE MODEL; TAU PHOSPHORYLATION; MEMORY IMPAIRMENT; REGULATES MEMORY; ACETYLATION; REDUCTION; TOXICITY; DEFICITS; SIRT1;
D O I
10.1155/2011/143269
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
Epigenetic modifications like DNA methylation and histone acetylation play an important role in a wide range of brain disorders. Histone deacetylases (HDACs) regulate the homeostasis of histone acetylation. Histone deacetylase inhibitors, which initially were used as anticancer drugs, are recently suggested to act as neuroprotectors by enhancing synaptic plasticity and learning and memory in a wide range of neurodegenerative and psychiatric disorders, such as Alzheimer's disease (AD) and Parkinson's disease (PD). To reveal the physiological roles of HDACs may provide us with a new perspective to understand the mechanism of AD and to develop selective HDAC inhibitors. This paper focuses on the recent research progresses of HDAC proteins and their inhibitors on the roles of the treatment for AD.
引用
收藏
页数:5
相关论文
共 50 条
  • [41] Targeting Mitophagy in Alzheimer's Disease
    Jayatunga, Dona P. W.
    Hone, Eugene
    Bharadwaj, Prashant
    Garg, Manohar
    Verdile, Giuseppe
    Guillemin, Gilles J.
    Martins, Ralph N.
    JOURNAL OF ALZHEIMERS DISEASE, 2020, 78 (04) : 1273 - 1297
  • [42] Targeting PPARalpha in Alzheimer's Disease
    D'Orio, Barbara
    Fracassi, Anna
    Ceru, Maria Paola
    Moreno, Sandra
    CURRENT ALZHEIMER RESEARCH, 2018, 15 (04) : 345 - 354
  • [43] Targeting Alzheimer's Disease With Aducanumab
    不详
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2016, 100 (06) : 580 - 580
  • [44] Synthesis and biological assessment of racemic benzochromenopyrimidinetriones as promising agents for Alzheimer's disease therapy
    Dgachi, Youssef
    Martin, Helene
    Bonet, Alexandre
    Chioua, Mourad
    Iriepa, Isabel
    Moraleda, Ignacio
    Chabchoub, Fakher
    Marco-Contelles, Jose
    Ismaili, Lhassane
    FUTURE MEDICINAL CHEMISTRY, 2017, 9 (08) : 715 - 721
  • [45] Targeting β-secretase with RNAi in neural stem cells for Alzheimer's disease therapy
    Zhonghua Liu
    Shengliang Li
    Zibin Liang
    Yan Zhao
    Yulin Zhang
    Yaqi Yang
    Minjuan Wang
    Feng Li
    Neural Regeneration Research, 2013, 8 (33) : 3095 - 3106
  • [46] Targeting β-secretase with RNAi in neural stem cells for Alzheimer's disease therapy
    Liu, Zhonghua
    Li, Shengliang
    Liang, Zibin
    Zhao, Yan
    Zhang, Yulin
    Yang, Yaqi
    Wang, Minjuan
    Li, Feng
    NEURAL REGENERATION RESEARCH, 2013, 8 (33) : 3095 - 3106
  • [47] Targeting histone-modifications in Alzheimer's disease. What is the evidence that this is a promising therapeutic avenue?
    Fischer, Andre
    NEUROPHARMACOLOGY, 2014, 80 : 95 - 102
  • [48] How promising are the latest monoclonal antibodies targeting amyloid-β for the treatment of early Alzheimer's disease?
    Beveridge, Jordan
    Kaniecki, Eileen
    Naidu, Aniketh
    Silverglate, Bret David
    Grossberg, George
    EXPERT OPINION ON EMERGING DRUGS, 2024, 29 (01) : 35 - 43
  • [49] Nanomedicine's promising therapy: magnetic drug targeting
    Kempe, Henrik
    Kates, Steven A.
    Kempe, Maria
    EXPERT REVIEW OF MEDICAL DEVICES, 2011, 8 (03) : 291 - 294
  • [50] Zinc-dependent deacetylases (HDACs) as potential targets for treating Alzheimer's disease
    Li, Yan
    Lin, Shuxian
    Gu, Zhicheng
    Chen, Lei
    He, Bin
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2022, 76